At the NIH, SBIR/STTR spending limits have increased to more than $1.0B in 2018; SBIR eligibility includes small businesses that are majority-owned by VCOCs; funding for Direct-to-Phase II activities have returned, and non-financial advisory services are now offered to small businesses to help them advance their product development programs. The path to commercialization is not met by funding alone, and many early stage companies required additional resources and networking opportunities to push their technologies forward. The NIH SBIR/STTR programs provide resources including I-Corps, C3i, commercialization assistance, and investor initiatives. This panel will illustrate how strategic initiatives at the NIH and collaborations with third party investors and strategic partners impact the technology development of federally-funded technologies to reach patients, clinicians, and the market to benefit human health.
Ability Level: All
Session ID: 503332